Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT.

Abou-Ismail, Mouhamed Yazan; Kanack, Adam J; Splinter, Noah P; Smock, Kristi J; Moser, Karen A; Padmanabhan, Anand

Abou-Ismail, Mouhamed Yazan; Kanack, Adam J; Splinter, Noah P; Smock, Kristi J; Moser, Karen A; Padmanabhan, Anand.

Afiliação

Abou-Ismail MY; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT.
Kanack AJ; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Splinter NP; Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
Smock KJ; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.
Moser KA; Associated Regional and University Pathologists Institute for Clinical and Experimental Pathology®, Salt Lake City, UT; and.
Padmanabhan A; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT.

Blood Adv ; 6(18): 5327-5329, 2022 09 27.

Article em En | MEDLINE | ID: mdl-35468623

Assuntos

Ad26COVS1; Vacina BNT162; COVID-19; Trombocitopenia; Trombose; Ad26COVS1/efeitos adversos; COVID-19/prevenção & controle; Humanos; Trombocitopenia/induzido quimicamente; Trombose/induzido quimicamente

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Trombocitopenia / Trombose / COVID-19 / Vacina BNT162 / Ad26COVS1 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google